IT1252687B - Vaccino di poxvirus ricombinante del virus del morbillo - Google Patents

Vaccino di poxvirus ricombinante del virus del morbillo

Info

Publication number
IT1252687B
IT1252687B ITMI913092A ITMI913092A IT1252687B IT 1252687 B IT1252687 B IT 1252687B IT MI913092 A ITMI913092 A IT MI913092A IT MI913092 A ITMI913092 A IT MI913092A IT 1252687 B IT1252687 B IT 1252687B
Authority
IT
Italy
Prior art keywords
recombinant poxvirus
virus
foreign dna
morbillo
vaccine
Prior art date
Application number
ITMI913092A
Other languages
English (en)
Inventor
Enzo Paoletti
Jill Taylor
Original Assignee
Virogenetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virogenetics Corp filed Critical Virogenetics Corp
Publication of ITMI913092A0 publication Critical patent/ITMI913092A0/it
Publication of ITMI913092A1 publication Critical patent/ITMI913092A1/it
Application granted granted Critical
Publication of IT1252687B publication Critical patent/IT1252687B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Viene descritto un poxvirus ricombinante per esempio vaccinia virus oppure poxvirus di canarino contenente DNA estraneo da Morbillivirus. In una forma di realizzazione, il DNA estraneo viene espresso in un ospite mediante la produzione di una glicoproteina del virus del morbillo. In un'altra forma di realizzazione, il DNA estraneo viene espresso in un ospite mediante la produzione di almeno due glicoproteine di virus del morbillo. Inoltre viene descritto un vaccino contenente il poxvirus ricombinante per provocare una risposta immunologica in un animale ospite inoculato con il vaccino. Mediante la presente invenzione si ottiene una protezione incrociata di cani contro il cimurro canino inoculando il cane con il poxvirus ricombinante.
ITMI913092A 1990-11-20 1991-11-20 Vaccino di poxvirus ricombinante del virus del morbillo IT1252687B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62161490A 1990-11-20 1990-11-20
US77686791A 1991-10-22 1991-10-22

Publications (3)

Publication Number Publication Date
ITMI913092A0 ITMI913092A0 (it) 1991-11-20
ITMI913092A1 ITMI913092A1 (it) 1993-05-20
IT1252687B true IT1252687B (it) 1995-06-23

Family

ID=27089007

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI913092A IT1252687B (it) 1990-11-20 1991-11-20 Vaccino di poxvirus ricombinante del virus del morbillo

Country Status (12)

Country Link
JP (2) JP3617668B2 (it)
AU (1) AU1253892A (it)
BE (1) BE1005908A5 (it)
CA (1) CA2096633A1 (it)
CH (1) CH683921A5 (it)
DE (2) DE4192786B4 (it)
FR (1) FR2669346B1 (it)
GB (2) GB2283021B (it)
IE (2) IE68404B1 (it)
IT (1) IT1252687B (it)
NL (2) NL195058C (it)
WO (1) WO1992008789A1 (it)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US6248333B1 (en) 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5756102A (en) * 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5989561A (en) * 1991-03-07 1999-11-23 Virogenetics Corporation Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses
KR100242671B1 (ko) * 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
JPH06505397A (ja) * 1991-03-20 1994-06-23 ヴァイロジェネティクス　コーポレイション マラリア組換体ポックスウイルス
EP1156102A1 (en) * 1991-06-14 2001-11-21 Virogenetics Corporation Immunodeficiency virus recombinant poxvirus vaccine
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
CN1089370C (zh) * 1994-12-08 2002-08-21 中国预防医学科学研究院病毒学研究所 表达麻疹病毒l4株血凝素及融合蛋白基因的重组痘苗病毒
WO1997028265A1 (en) * 1996-02-05 1997-08-07 University Of Massachusetts Medical Center Measles immunization by dna transcription unit inoculation
CA2289731A1 (en) 1997-05-09 1998-11-12 The United States Of America, Represented By The Secretary, Department O F Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
EP1095948A1 (en) * 1999-10-28 2001-05-02 Universitätsklinikum Freiburg Idiotype vaccines
DE60234018D1 (de) 2001-03-08 2009-11-26 Univ Emory Mva-exprimierende modifizierte hiv-envelope-, gag-, und pol-gene
AR052743A1 (es) * 2006-04-11 2007-03-28 Inst Nac De Tecnologia Agropec Vector plasmidico de transferencia y virus canarypox recombinante

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2617715B1 (fr) * 1987-07-07 1990-08-31 Transgene Sa Vecteur viral et adn recombinant codant pour une ou des proteines de surface (ha et/ou f) d'un morbillivirus, culture cellulaire infectee, proteines obtenues, vaccin et anticorps obtenus
DE10399032I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
FR2632863B2 (fr) * 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
JPH01218590A (ja) * 1988-02-29 1989-08-31 Toa Nenryo Kogyo Kk 組換ワクチニアウイルスを用いたリンダペスト（牛疫）ウイルスワクチン

Also Published As

Publication number Publication date
GB2283021B (en) 1995-07-05
ITMI913092A0 (it) 1991-11-20
GB2283021A (en) 1995-04-26
FR2669346B1 (fr) 1995-07-21
CA2096633A1 (en) 1992-05-21
CH683921A5 (fr) 1994-06-15
WO1992008789A1 (en) 1992-05-29
JP2005040129A (ja) 2005-02-17
GB9309414D0 (en) 1993-07-14
AU1253892A (en) 1992-06-11
BE1005908A5 (fr) 1994-03-08
GB2264949B (en) 1995-07-05
NL195095C (nl) 2004-01-21
FR2669346A1 (fr) 1992-05-22
GB9500214D0 (en) 1995-03-01
NL195058C (nl) 2003-07-01
JPH06502996A (ja) 1994-04-07
DE4192786B4 (de) 2006-08-24
IE913960A1 (en) 1992-05-20
DE4192786T1 (de) 1994-01-13
IE68404B1 (en) 1996-06-12
GB2264949A (en) 1993-09-15
NL9900036A (nl) 2003-10-01
JP3824619B2 (ja) 2006-09-20
JP3617668B2 (ja) 2005-02-09
NL9120026A (nl) 1993-09-01
ITMI913092A1 (it) 1993-05-20
IE71643B1 (en) 1997-02-26

Similar Documents

Publication Publication Date Title
IT1252687B (it) Vaccino di poxvirus ricombinante del virus del morbillo
DE3677494D1 (de) Virus-impfstoff.
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
DK0592546T3 (da) Immundeficiens-virus rekombinant poxvirus-vaccine
IE802225L (en) Vaccine stabilizer
EP0816499A3 (en) Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma
ATE79548T1 (de) Herpes simplex virus subunitimpfstoff.
DE68920610D1 (de) Rekombinantes Virus der Marekschen Krankheit und Vakzin.
ATE47524T1 (de) Hundeparvovirus-impfstoffe.
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
BR9303226A (pt) Processo e vacina para produzir anticorpos ou imundade mediada por celulas e adenovirus recombinante
HUP0001991A2 (hu) Varicella Zoster vírus 63-as géntermékkel szembeni vakcinák
DE3579617D1 (de) Lebender gereinigter impfstoff gegen die marek'sche krankheit.
DE69332264D1 (de) Mutanten des infektiösen rinder rhinotracheitis-virus und impfstoffe
ATE189702T1 (de) Das für das pferde herpes-virus typ 1 glykoprotein d, kodierende gen, sein genprodukt, antikörper und ihre verwendung
BR9403202A (pt) Método de produção de anticorpos ou imunidade mediada por célula a vírus de imunodeficiência humana, método de proteção contra infecção de vírus de imunodeficiência humana, vacina e adenovírus recombinante
DK0623172T3 (da) Rekombinant Mareks sygdomsvirus-poxvirusvaccine
ATE86119T1 (de) Lebendvaccine fuer ansteckungskrankheiten von kueken.
DE69226980D1 (de) Rekombinanter Varicella-Zoster-Virus-Vektor
DE69720024D1 (de) Immunisierungsverfahren in zwei schritten gegen pyramyxoviridae-viren unter verwendung abgeschwächter viraler stämme und preparation von proteinuntereinheiten
ATE318300T1 (de) Isolierte stämme von staphylococcus aureus und daraus hergestellte impfstoffe
DK0491125T3 (da) Vacciner til equine herpesvira samt deres fremstilling
AU532186B2 (en) Herpes virus vaccine
NO942075L (no) Rekombinante virus omfattende kunstig proteolytisk spaltingssete
WO2002020041A3 (en) Eia vaccine and diagnostic

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19971125